LeMaitre Vascular (NASDAQ:LMAT) Now Covered by Analysts at Lake Street Capital

Lake Street Capital began coverage on shares of LeMaitre Vascular (NASDAQ:LMAT) in a report published on Friday, StockNewsAPI reports. The brokerage issued a buy rating and a $105.00 target price on the medical instruments supplier’s stock.

A number of other research analysts also recently commented on LMAT. Roth Capital upgraded LeMaitre Vascular to a strong-buy rating in a research note on Friday, May 31st. StockNews.com downgraded LeMaitre Vascular from a buy rating to a hold rating in a research note on Thursday, July 25th. Stifel Nicolaus upgraded LeMaitre Vascular from a hold rating to a buy rating and upped their price target for the stock from $59.00 to $75.00 in a research note on Friday, April 26th. Barrington Research upped their price target on LeMaitre Vascular from $69.00 to $79.00 and gave the stock an outperform rating in a research note on Friday, May 3rd. Finally, Roth Mkm reiterated a buy rating and set a $100.00 price target on shares of LeMaitre Vascular in a research note on Friday, May 31st. Three research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of Moderate Buy and a consensus target price of $83.71.

LeMaitre Vascular Stock Performance

NASDAQ:LMAT traded down $1.24 during trading hours on Friday, hitting $85.01. 348,354 shares of the company’s stock traded hands, compared to its average volume of 157,693. The firm has a market cap of $1.91 billion, a P/E ratio of 56.30, a P/E/G ratio of 2.63 and a beta of 0.89. LeMaitre Vascular has a twelve month low of $44.27 and a twelve month high of $91.76. The stock’s fifty day moving average price is $82.69 and its two-hundred day moving average price is $71.68.

LeMaitre Vascular (NASDAQ:LMAT) last issued its earnings results on Thursday, August 1st. The medical instruments supplier reported $0.52 EPS for the quarter, beating analysts’ consensus estimates of $0.47 by $0.05. LeMaitre Vascular had a return on equity of 12.63% and a net margin of 18.33%. The firm had revenue of $55.85 million for the quarter, compared to the consensus estimate of $54.98 million. During the same quarter in the previous year, the company posted $0.37 earnings per share. The business’s quarterly revenue was up 11.4% compared to the same quarter last year. On average, equities research analysts predict that LeMaitre Vascular will post 1.77 earnings per share for the current year.

LeMaitre Vascular Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, August 29th. Shareholders of record on Thursday, August 15th will be issued a $0.16 dividend. The ex-dividend date is Thursday, August 15th. This represents a $0.64 annualized dividend and a yield of 0.75%. LeMaitre Vascular’s dividend payout ratio (DPR) is 42.38%.

Insider Buying and Selling at LeMaitre Vascular

In other LeMaitre Vascular news, CEO George W. Lemaitre sold 27,030 shares of the company’s stock in a transaction that occurred on Monday, July 15th. The stock was sold at an average price of $86.27, for a total value of $2,331,878.10. Following the completion of the transaction, the chief executive officer now owns 1,958,328 shares of the company’s stock, valued at approximately $168,944,956.56. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other news, CEO George W. Lemaitre sold 27,030 shares of the stock in a transaction that occurred on Monday, July 15th. The stock was sold at an average price of $86.27, for a total value of $2,331,878.10. Following the completion of the transaction, the chief executive officer now directly owns 1,958,328 shares of the company’s stock, valued at approximately $168,944,956.56. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO George W. Lemaitre sold 8,000 shares of the stock in a transaction that occurred on Wednesday, May 8th. The stock was sold at an average price of $75.30, for a total value of $602,400.00. Following the completion of the transaction, the chief executive officer now directly owns 2,079,128 shares of the company’s stock, valued at $156,558,338.40. The disclosure for this sale can be found here. Insiders sold a total of 127,437 shares of company stock valued at $10,076,242 in the last quarter. Corporate insiders own 10.79% of the company’s stock.

Hedge Funds Weigh In On LeMaitre Vascular

A number of hedge funds have recently modified their holdings of the stock. Jackson Creek Investment Advisors LLC acquired a new position in shares of LeMaitre Vascular in the 2nd quarter worth approximately $1,158,000. Versor Investments LP bought a new stake in LeMaitre Vascular during the 2nd quarter worth approximately $387,000. nVerses Capital LLC grew its position in LeMaitre Vascular by 33.3% during the 2nd quarter. nVerses Capital LLC now owns 800 shares of the medical instruments supplier’s stock worth $66,000 after acquiring an additional 200 shares during the last quarter. Van ECK Associates Corp bought a new stake in LeMaitre Vascular during the 2nd quarter worth approximately $75,000. Finally, Kings Path Partners LLC bought a new stake in LeMaitre Vascular during the 2nd quarter worth approximately $1,694,000. 84.64% of the stock is owned by institutional investors and hedge funds.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.